It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Pharmaceutical
Gemin X Pharmaceuticals developed cancer therapeutics focussed on the cell death pathway. The lead candidate, GX15-070, reinitiates programmed cell death and apoptosis. Gemin X was acquired by Cephalon in 2011 for $525 million.
Location
Canada
History
Acquired by Cephalon in 2011 for $525 million
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
